United States

OBJECTIVE: To contrast the diagnostic accuracy of 3D ultrasonographic markers of ovarian morphology to 2D ultrasonography and serum anti-Müllerian hormone (AMH) levels for detection of polycystic ovary syndrome (PCOS). Any gains in diagnostic accuracy when combining ovarian markers was also explored.

METHODS: 30 women with PCOS based on the National Institutes of Health (NIH) criteria and 30 age- and body mass index (BMI)-matched controls were evaluated. Transvaginal ultrasound scans (GE Voluson E or S Series; 5-12 MHz) and blood draws were conducted during the early follicular phase for women with regular cycles or at a random time for women with irregular cycles. Ovarian images were analyzed for the number of 2-9mm antral follicles in the entire ovary (FNPO), number of 2-5mm antral follicles (FNPO2-5mm) and 6-9mm antral follicles (FNPO6-9mm), and ovarian volume (OV) using 3D and 2D ultrasonography by one of six trained raters. 3D versus 2D ovarian markers were compared using Bland-Altman agreement statistics for matched-pair analysis. Diagnostic accuracy of ovarian markers for PCOS was determined by Receiver Operating Characteristic (ROC) curve analysis. Stepwise logistic regression analysis determined if combinations of ultrasonographic markers or AMH yielded greater diagnostic potential than single parameters.

RESULTS: 3D measurements of FNPO, FNPO2-5mm, and OV had greater diagnostic accuracy for PCOS compared to their 2D counterparts. The most accurate markers for PCOS were 3D FNPO (AUC=0.938) and 3D FNPO2-5mm (AUC=0.933), followed by 2D FNPO (AUC=0.922) and 2D FNPO2-5mm (AUC=0.906). Despite overall agreement between 3D and 2D FNPO measures, 3D ultrasonography overcounted FNPO2-5mm (2.00 ± 3.68, P=0.006) and undercounted FNPO6-9mm (-3.00 ± 3.49, P&lt;0.001) in women with PCOS. AMH (AUC=0.898) had greater diagnostic accuracy than 3D and 2D OV (AUC=0.854 and 0.849, respectively), but remained inferior to both 3D and 2D follicle counts. The addition of OV or AMH did not improve diagnostic accuracy for follicle counts. However, the addition of AMH did substantially improve the diagnostic accuracy of 3D OV (AUC=0.918) and 2D OV (AUC=0.911).

CONCLUSIONS: 3D ultrasonographic markers of ovarian morphology outperformed 2D markers in the diagnosis of PCOS, with 3D markers of follicle excess being the most accurate measure overall. AMH had inferior diagnostic accuracy compared to FNPO across both modalities but was superior to OV. Addition of AMH improved the predictive power of OV on 2D and 3D ultrasonography thereby offering a robust alternative when image quality prevents an accurate assessment of follicle counts.

(This study was funded by the National Institutes of Health Grant [R01HD09374, R56HD089962, UL1 TR000457-06, T32DK007158-41] and the Canadian Institute of Health Research [FRN 146182].)


AE-PCOS 2022

3D Markers of ovarian morphology outperform 2D ultrasonography and Anti-Müllerian hormone in the diagnosis of PCOS

### Welcome to the AE-PCOS Society's 20th Annual Meeting!


The AE-PCOS Society’s 20th Annual Meeting's theme will be Reflections and Directions. The meeting will aim to incorporate the perspectives of both long-time, contributing members of the Society and newer members of the Society, while highlighting the latest research findings in PCOS-related clinical and basic research.

The recorded content will be available to registrants only for three months after the meeting. 


To gain access to this event page you are required to register. 

For tickets to the event, please register [here](https://secure.ae-society.org/np/clients/aesociety/eventRegistration.jsp?forwardedFromSecureDomain=1&event=2). 

Please register for the AE-PCOS 2022 Conference to join the event.

The AE-PCOS Society’s 20th Annual Meeting's theme are Reflections and Directions. The meeting aims to incorporate the perspectives of both long-time, contributing members of the Society and newer members of the Society, while highlighting the latest research findings in PCOS-related clinical and basic research.

OBJECTIVE: To contrast the diagnostic accuracy of 3D ultrasonographic markers of ovarian morphology to 2D ultrasonography and serum anti-Müllerian hormone (AMH) levels for detection of polycystic ovary syndrome (PCOS). Any gains in diagnostic accuracy when combining ovarian markers was also explored.

METHODS: 30 women with PCOS based on the National Institutes of Health (NIH) criteria and 30 age- and body mass index (BMI)-matched controls were evaluated. Transvaginal ultrasound scans (GE Voluson E or S Series; 5-12 MHz) and blood draws were conducted during the early follicular phase for women with regular cycles or at a random time for women with irregular cycles. Ovarian images were analyzed for the number of 2-9mm antral follicles in the entire ovary (FNPO), number of 2-5mm antral follicles (FNPO2-5mm) and 6-9mm antral follicles (FNPO6-9mm), and ovarian volume (OV) using 3D and 2D ultrasonography by one of six trained raters. 3D versus 2D ovarian markers were compared using Bland-Altman agreement statistics for matched-pair analysis. Diagnostic accuracy of ovarian markers for PCOS was determined by Receiver Operating Characteristic (ROC) curve analysis. Stepwise logistic regression analysis determined if combinations of ultrasonographic markers or AMH yielded greater diagnostic potential than single parameters.

RESULTS: 3D measurements of FNPO, FNPO2-5mm, and OV had greater diagnostic accuracy for PCOS compared to their 2D counterparts. The most accurate markers for PCOS were 3D FNPO (AUC=0.938) and 3D FNPO2-5mm (AUC=0.933), followed by 2D FNPO (AUC=0.922) and 2D FNPO2-5mm (AUC=0.906). Despite overall agreement between 3D and 2D FNPO measures, 3D ultrasonography overcounted FNPO2-5mm (2.00 ± 3.68, P=0.006) and undercounted FNPO6-9mm (-3.00 ± 3.49, P<0.001) in women with PCOS. AMH (AUC=0.898) had greater diagnostic accuracy than 3D and 2D OV (AUC=0.854 and 0.849, respectively), but remained inferior to both 3D and 2D follicle counts. The addition of OV or AMH did not improve diagnostic accuracy for follicle counts. However, the addition of AMH did substantially improve the diagnostic accuracy of 3D OV (AUC=0.918) and 2D OV (AUC=0.911).

CONCLUSIONS: 3D ultrasonographic markers of ovarian morphology outperformed 2D markers in the diagnosis of PCOS, with 3D markers of follicle excess being the most accurate measure overall. AMH had inferior diagnostic accuracy compared to FNPO across both modalities but was superior to OV. Addition of AMH improved the predictive power of OV on 2D and 3D ultrasonography thereby offering a robust alternative when image quality prevents an accurate assessment of follicle counts.

(This study was funded by the National Institutes of Health Grant [R01HD09374, R56HD089962, UL1 TR000457-06, T32DK007158-41] and the Canadian Institute of Health Research [FRN 146182].)


technical paper

OBJECTIVE: Polycystic Ovary Syndrome (PCOS) is associated with increased cardiometabolic risk factors and incidence of cardiovascular disease (CVD). Currently, early screening of dyslipidemia, atherosclerotic CVD (ACVD) and heart function are not routine in the primary care of high-risk young women with and without PCOS. The aim of this study was to provide evidence-based research to aid the development of assessment guidelines for early detection of dyslipidaemia, cardiac dysfunction and ACVD in high-risk young women with and without PCOS. 

METHODS: A case-control study in high-cardiometabolic risk (body mass index (BMI>25) women aged 25-45 years with and without PCOS, matched for age and body mass index, and healthy weight controls was conducted. The main outcome measures included blood lipids, apoB-lipoproteins, carotid intima-media thickness (cIMT), carotid plaque and cardiac function using ultrasound and 2D/3D echocardiography. 

RESULTS: High-risk women with (n-45) and without PCOS (n=20) had a 25% higher total apoB, 30% higher non-HDL-C and 50% higher triglycerides compared to age-matched health weight controls (n=10). PCOS tended to have higher plasma triglycerides, total ApoB, non-HDL-C and remnant cholesterol compared to BMI-matched controls Those with PCOS had a significantly lower HDL-C compared to both BMI-age-matched and health-weight controls. Carotid plaque was 3- and 8-fold higher in those with PCOS compared to BMI-matched and healthy weight controls, respectively. Those with PCOS and BMI-matched controls had increased cIMT by 15% and early left ventricular global longitudinal strain by 10%, compared to healthy-weight controls.

CONCLUSIONS: High-risk PCOS and BMI-matched controls have early impairment in global cardiac function and increased ACVD, and this is associated with an atherogenic dyslipidemic profile. These results suggest early primary prevention screening and a risk-stratification model may be warranted in this high-risk population of young women to reduce risk of premature development and incidence of CVD.

This research is funded by Women and Children’s Health Research Institute and Mazankowski Heart Research Institute


Early Atherosclerosis in High-Risk Young Women With and Without Polycystic Ovary Syndrome 

OBJECTIVE: PCOS is the most common metabolic-endocrine disorder that can impact health and quality of life over a lifespan. It is important we understand the scope of health outcomes that impact the health and quality of life of those with PCOS in order to improve health care in this population. The aim of this study was to determine the incidence of co-morbidities in PCOS compared to an age-matched population. 
METHODS: We conducted a retrospective observational case-control study in those diagnosed with PCOS and age-matched controls using the Alberta Health Services Health Analytics database from 2002-2019 in Alberta, Canada. 
RESULTS: The incidence of high blood pressure, high blood lipids, diseases of the heart, kidney, gastrointestinal tract, pre-diabetes, eating disorders, mental illness, depression-anxiety, rheumatoid arthritis, respiratory infections and all cancers was 20-40% (p<0.0001) higher in PCOS (n=16531) compared to controls (n=49335). Overweight-obesity, non-alcoholic liver disease, Type 1 diabetes (T1D) and T2D had a 3-fold greater incidence in PCOS (p<0.0001). Cardiovascular disease and cerebrovascular disease were 60% higher in PCOS compared to controls (p<0.0001). 
CONCLUSION: These findings indicate PCOS is associated with a significantly greater incidence of co-morbidities and adverse health outcomes. This data provides evidence of the potential economic health care burden and lower quality of life in those with PCOS. The data may also indicate a need to improve education of patients and clinicians in raising awareness of health risks and implementation of preventative health care in this high-risk population. 
This work was funded by the Women and Children’s Health Research Institute and University of Alberta Medical Research Foundation.


PCOS is Associated with Increased Incidence of Co-morbidities in a Canadian Population Cohort

OBJECTIVE: Ovulatory dysfunction is usually caused by an endocrine disorder, of which polycystic ovary syndrome (PCOS) is the most common cause. PCOS is associated with normal estrogen levels and can be characterized by oligo-/anovulation resulting in decreased progesterone levels. It is suggested that decreased progesterone levels may lead to more autoimmune diseases in women with PCOS. In addition to PCOS, hyperprolactinemia (HPRL) is also a common endocrine disorder in women of reproductive age and it is often claimed that there is an association between HPRL and PCOS. The aims of this study are to determine whether women with PCOS have 1) a higher prevalence of thyroid dysfunction, 2) an increase of anti-thyroid peroxidase antibodies (TPOab), and 3) a higher prevalence of hyperprolactinemia compared to controls. 

METHODS: This retrospective cross-sectional study contains data of 1432 women with PCOS, who were diagnosed at a tertiary hospital (between 1993-2000), and 299 women without PCOS who conceived spontaneously and participated in a study between 2004-2007, of which 168 women gave birth to a child with a congenital heart disease and 131 women gave birth to a healthy child.

RESULTS: The median age of women with PCOS was 28.2 years [interquartile range (IQR) 24.6 - 31.7] and 32.8 years [IQR 29.7 - 35.8] of the controls (p<0.01). Median BMI of women with PCOS was higher compared to the controls (25.2 kg/m2 [IQR 21.9 - 30.8] versus 24.4 kg/m2 [IQR 22.3 - 17.5]; p<0.01). The prevalence of thyroid diseases in PCOS women was similar compared to controls (1.9% versus 2.7%; p=0.39 for hypothyroidism, 3.2% versus 2.7%; p=0.59 for subclinical hypothyroidism, and 0.5% versus 0%; p=0.99 for hyperthyroidism). TSH levels and the prevalence of positive TPOab were the same in both groups (1.55 mIU/L versus 1.48 mIU/L; p=0.54 and 5.7% versus 8.7%; p=0.12). FT4 levels were higher in women with PCOS (18.1 pmol/L versus 17.7 pmol/L; p<0.05). The prevalence of HPRL was higher in PCOS patients (7.0% versus 3%; p<0.05) and in this group 0.5% had a pituitary abnormality, such as macroprolactinomas. All these results were adjusted for age and BMI. 

CONCLUSIONS: The prevalence of thyroid diseases is not increased in women with PCOS. Although FT4 levels were significantly higher, they were well within the normal range. Hence, this finding is probably without any clinical relevance. Moreover, there was no difference in the prevalence of positive TPOab, indicating a similar risk for thyroid disease in women with PCOS versus controls. Although HPRL was more prevalent in PCOS patients this might be due to selection bias, because patients with HPRL are less likely to conceive spontaneously compared to our controls. However, as recommended in the guideline, thyroid diseases and HPRL should be excluded in women with symptoms of ovulatory dysfunction.

The Prevalence Of Thyroid Dysorders And Hyperprolactinemia In Women With Pcos Compared To Controls

BACKGROUND: The association between polycystic ovary syndrome (PCOS) and non-alcoholic fatty liver disease (NAFLD) is well documented and believed to be due to associated metabolic risk factors. NAFLD prevalence in PCOS is estimated to be between 25.4% and 68.8%. Saroglitazar Magnesium, a dual PPAR α/γ agonist, demonstrated lipid and glucose lowering effects with good safety profile in various clinical studies. In Letrozole-induced PCOS animal models, repeated doses of Saroglitazar magnesium reduced cystic follicle, improved insulin sensitivity, increased serum FSH, decreased LH/FSH ratio, decreased serum testosterone, and normalized ovary weight. 
OBJECTIVE: We are currently conducting a proof of concept study to evaluate the efficacy and safety of Saroglitazar Magnesium 4 mg in adult females (≥ 18 years) women with well characterized PCOS and NAFLD by measuring the magnetic resonance imaging proton-density fat-fraction (MRI-PDFF). The secondary objectives are changes in alanine aminotransferase (ALT) aspartate aminotransferase (AST), liver stiffness measurement (LSM), controlled attenuation parameter (CAP), serum-glucose, body mass index (BMI), body weight, lipid-profile, sex hormone binding globulin (SHBG), ovarian function and free androgen index (FAI). 
METHODS: Multicentre, phase 2a, randomized, double-blind, placebo-controlled study is currently ongoing across eight centres in US (NCT03617263) and Mexico. 90 eligible patients with ALT level ≥ 38 U/L & hepatic fat fraction ≥10% by MRI-PDFF are randomly assigned to either Saroglitazar Magnesium 4 mg or placebo arms in 1:1 ratio for 24 weeks. 
RESULTS: Of the 122 subjects (mean age of 29.9 ± 7 years) who have been screened from December 2018 to August 2022, 51 (41.8%) subjects have been randomized so far. Major reason of screening failure was ALT < 38 U/L in 58 (86.6%) patients. Subjects with screen failures had significantly lower mean ALT levels (27.6 ± 20.6 U/L vs 53.6 ± 44.5 U/L, p<0.001), lower AST levels (21.8 ± 18.2 U/L vs 36.0 ± 28.4 U/L, p=0.002), lower FAI (1.13 ± 0.97 vs 1.66 ± 1.16, p=0.007) and higher SHBG (66.7 ± 80.1 vs 42.6 ± 50.4, p=0.045) compared with subjects without screen failures at baseline. No other significant differences were observed. Of 51 subjects enrolled, 45 (88.2%) patients were obese, 37 (72.5%) had hyperinsulinemia, 47 (92.2%) had Hyperandrogenism, 8 (15.7%) had impaired fasting glucose and 5 (9.8%) patients had dyslipidaemia.
CONCLUSION: This is the only prominent ongoing interventional study in US for treatment of NAFLD in women with PCOS. Above baseline data will help endocrinologist, gynaecologist and hepatologist in better collaboration and awareness of the disease amongst PCOS patients. The results of this clinical trial will provide a strong basis for long term evaluation and potential management and treatment of patients with PCOS and NAFLD. 


Evidences VII – Ongoing Proof Of Concept Study Of Saroglitazar In Treatment Of NaFlD In Women With PCOS

OBJECTIVE: Polycystic ovary syndrome (PCOS), is associated with reduced health-related quality of life (QOL) and increased risk for depression and anxiety. These associations are partly due to the stressful and stigmatizing nature of PCOS symptoms, including hirsutism and negative body image stemming from BMI. However, the impact of the cumulative wear and tear in the stress response system (i.e. allostatic load (AL)), and of metabolic syndrome on these QOL outcomes is unknown. We assessed how AL and metabolic syndrome relate to physical and mental health related QOL in women with PCOS. 
METHODS: We performed a secondary analysis of baseline data from a randomized control trial (OWL-PCOS) in women with PCOS defined by Rotterdam criteria. Physical and mental health related QOL were assessed by the SF36 and PCOSQ. AL was calculated using the 12 factors: IGF-1, HDL, LDL, triglycerides, fasting glucose, fasting insulin, creatinine, systolic blood pressure, diastolic blood pressure, heart rate, waist-to-hip ratio, and BMI. High risk categories were calculated as the 75th percentile for all factors except for HDL in which the 25th percentile was used. An AL index was calculated for each participant as the sum of the number of factors in the risk category (0-12), with higher scores indicating more physiological dysregulation in the stress response system. We defined a high level of AL as an ALI of 4, based on convention. Metabolic syndrome was classified as meeting 3 of 5 NIH criteria. Wilcoxon rank sum tests were used to assess differences in QOL measures between high vs low AL, and with vs without metabolic syndrome. All analyses were performed in RStudio version 2022.07.1.
RESULTS: Among 90 women with PCOS, the mean age was 29 years old, the majority of which were White (84%), non-Hispanic (93%), nulliparous (83%) and not on any medications for depression (97%) or anxiety (98%). Thirty-six women had high AL and 27 women had metabolic syndrome. Women with high AL, had significantly higher summary scores on the SF36 Mental Component (p = 0.012) and lower scores on the SF36 Physical Component (p = 0.001), indicating higher mental health QOL and lower physical health QOL. On the PCOSQ, women with high AL had higher Emotional Wellbeing scores (p = 0.013), but no differences in Physical Wellbeing and General Wellbeing scores. Women with metabolic syndrome had lower SF36 Physical Component summary scores (p=0.039), indicating lower physical health related QOL. 
CONCLUSION: These findings suggest that among the constellation of symptoms experienced by women with PCOS, AL and metabolic syndrome are not primary drivers of adverse mental health outcomes in this population. 


Do allostatic load and metabolic syndrome contribute to mental health outcomes in women with polycystic ovary syndrome?

OBJECTIVE: Polycystic ovary syndrome (PCOS) is associated with increased risk for depression and anxiety, partly driven by BMI, hirsutism, and genetic factors. Although PCOS increases the odds of hypertension (HTN) by 1.5, the co-occurrence of PCOS + HTN in relation to symptoms of depression and anxiety is not well understood. Furthermore, few studies focus solely on these symptoms in Black women with PCOS. Here, we examine the impact of HTN on depression, anxiety, and fatigue symptoms in Black women with PCOS. 
METHODS: We preformed preliminary data analysis of a single cohort study of symptoms in adult Black women with PCOS or with PCOS + HTN. Both diagnoses were obtained from medical records. Depressive symptoms were measured by the PROMIS Depression short-form and the CESD-10. Anxiety was measured by the PROMIS Anxiety short-form and the state scale of the State-Trait Anxiety Inventory (STAI). Fatigue was measured by the PROMIS Fatigue short-form and the Multidimensional Fatigue Inventory (MFI). Wilcoxon rank sum tests were used to assess differences in symptoms between PCOS vs PCOS + HTN. All analyses were performed in RStudio version 2022.07.1.
RESULTS: Among 32 Black women with PCOS, the mean age was 34.7 years old, and the mean BMI was 39.8. Nine of the 32 women had PCOS + HTN. Women with PCOS + HTN demonstrated higher fatigue on the MFI (p = 0.015), more severe depression on the PROMIS Depression (p = 0.039) and CESD-10 (p = 0.046), and more severe anxiety symptoms on the STAI (p = 0.007). For those with PCOS + HTN, mean scores exceed cut points for clinical depression on the CESD-10 and clinical anxiety on the STAI. Women with PCOS + HTN also demonstrated a trend for higher fatigue on the PROMIS Fatigue as well as higher anxiety on the PROMIS Anxiety. 
CONCLUSION: Our findings highlight that the co-occurrence of HTN and PCOS in Black women may contribute to the severity of depression, anxiety, and fatigue symptoms. Our study also points toward the need to better understand the symptom experience of minority groups with PCOS, including racial, ethnic, sex, and gender. 
(Funding: 1P30NR-18090 [Pilot PI: LN])

Depression, Anxiety & Fatigue Among Black Women With Pcos With and Without Hypertension

Comparing Rotterdam and NIH Criteria: Women with PCOS have increased risk for cardiovascular diseases regardless of diagnostic criteria used

OBJECTIVE: Polycystic Ovary Syndrome (PCOS) is associated with insulin resistance, hyperandrogenism, and dyslipidemia, but the progression of type 2 diabetes mellitus in Chinese women with PCOS have only been investigated in clinic-based study population. Therefore, a population-based longitudinal study can help establish the overall risk of diabetes progression in Chinese women with PCOS. 
METHODS: This territory-wide, retrospective cohort study evaluated data extracted from the Hong Kong Diabetes Surveillance Database (HKDSD) between year 2000 and 2019. The subjects were women with PCOS (n=3978) identified based on the ICD-9 code for PCOS diagnosis, whilst women without PCOS served as controls (n=39780). Women with PCOS were age-matched at a ratio of 1:10 to a set of non-PCOS controls. Primary outcome was the first record of incident diabetes. Crude rates for diabetes were presented, and time to diabetes was analyzed using Cox proportional hazard models. 
RESULTS: The mean follow-up was 6.3 ± 4.2 and 7.0 ± 4.3 years in women with PCOS (baseline mean age: 28.53 ± 7.39 years old) and controls (baseline mean age: 28.93 ± 7.62 years old), respectively.  In the cohort of women with PCOS, the crude incidence rate of diabetes was 21.48 per 1000 person-years (95% CI 19.56 -23.40) compared with 3.51 (95% CI 3.29-3.73) in the control cohort. The crude hazard ratio for the development of diabetes in Chinese women with PCOS was 6.25 (95% CI: 5.60-6.98, p<0.001). All participants were further stratified by age groups (≤19, 20-29, 30-39 and ≥40 years old). The incidence rate of diabetes was significantly higher in women diagnosed with PCOS than that of the age-matched control cohort, especially if PCOS was diagnosed at a younger age. Although the excess risk of developing diabetes decreased with increasing age at diagnosis, it remained significantly higher in women with PCOS across all age groups. Nevertheless, diabetes was diagnosed on average 5 years earlier in women with PCOS compared to control counterpart (mean onset of diabetes in PCOS: 34.65 ± 8.13 vs control: 39.61 ± 9.38, p<0.001). 
CONCLUSIONS: The risk of developing diabetes is markedly increased in Chinese women with PCOS compared with women without PCOS. Women diagnosed with PCOS at a younger age have the highest relative risk of developing diabetes when compared to non-PCOS women, suggesting regular glycaemic status screening might be required in order to detect diabetes at an early stage. 

Increased risk of diabetes across the reproductive age range in women with PCOS: A territory-wide retrospective analysis from the Hong Kong diabetes surveillance database

Gut microbiota appears to be implicated in the development of a wide range of diseases affecting different organs and systems of the body. Alterations in composition, diversity and metabolites derived from the gut microbiota have been reported in preliminary animal and human studies of polycystic ovary syndrome (PCOS) indicating that microbiota might potentially be involved in development of the syndrome and its long-term metabolic health consequences. Our results suggest that gut microbiome of both lean and obese PCOS patients with full phenotype shows compositional alterations with similar bacterial richness and diversity compared to healthy women and that oral contraceptive use does not alter composition of gut microbiota in the syndrome. However, microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and its precursors closely linked to cardiovascular disease are elevated in PCOS and oral contraceptive use is associated with reduction of these microbiome-dependent metabolites. Larger studies are needed to investigate whether dysbiosis has an implication in pathogenesis of PCOS and whether it could give rise to novel treatment opportunities. 

Premium content

3D Markers of ovarian morphology outperform 2D ultrasonography and Anti-Müllerian hormone in the diagnosis of PCOS

Downloads

Next from AE-PCOS 2022

Early Atherosclerosis in High-Risk Young Women With and Without Polycystic Ovary Syndrome

Similar lecture

Walter Futterweit Award in Clinical Research

Stay up to date with the latest Underline news!

PRESENTATIONS

CONFERENCES

COMPANY

RESOURCES